Correlation of elevated cardiac troponin T level with severity and in-hospital outcomes in patients with acute ischemic stroke.

Salam Naser Zangana[1*] Abdulkareem A. Al-Othman[2] Azad Anwar Hamad[3]

[1*] (Corresponding author) M.B.Ch.B. , D.M., C.A.B.M.S., F.I.C.M.S. Senior Lecturer and Consultant Physician, Department of Medicine, College of Medicine, Hawler Medical University, Erbil-Iraq

[2] M.B.Ch.B., F.I.C.M.S. Professor of Medicine, Department of Medicine, College of Medicine, Hawler Medical University.

[3] M.B.Ch.B., F.I.C.M.S/Neurology. Senior Lecturer, Department of Medicine, College of Medicine, Hawler Medical University,

Abstract

Background: Although elevated cardiac troponin T (cTnT) is a specific marker of acute coronary syndrome (ACS), its increment in patients with acute ischemic stroke is not clear. The aim of this study is to identify the relationships between high cTnT levels and stroke severity and some in-hospital outcomes.

Methods: This observational, cross-sectional study was conducted on 100 patients with acute ischemic stroke in Rizgary teaching hospital from January 2016 to January 2017. Patients were divided into two groups; group 1 patients (n=61) with normal cTnT level and group 2 patients (n=39) with elevated cTnT level. The relationships between cTnT levels and stroke severity and some in-hospital outcomes were assessed and compared between the two groups.

Results: In this study, cTnT was raised in 39 patients (39%). Patients with elevated cTnT levels were mainly males, had a significant higher prevalence of hypertension and diabetes mellitus than the normal cTnT group ($P<0.001$, for all). Systolic blood pressure (SBP) and total cholesterol were significantly higher ($P<0.008$ and <0.001, respectively) in group II patients than in group I. In addition, group II patients had more ECG changes, higher stroke scale and higher length of stay in hospital than in group I patients, and the differences were significant ($P<0.001$, for all). The incidence of aspiration pneumonia, seizures, hemorrhage inside the infarcted area, and death was significantly higher ($P<0.001$, for all) in group II patients than in group I patients.

Conclusion: Elevated serum cTnT level at hospital admission is highly correlated with severity and poor in-hospital outcomes in patients with acute ischemic stroke.

Key words: Cardiac troponin T (cTnT), Acute ischemic stroke, In-hospital outcomes.

Introduction:

Stroke is a common cause of mortality and morbidity worldwide.[1] The correlation between stroke and heart disease is established in many studies.[2] Embolism due to cardiac disease accounts for 15-20% of all strokes and after a stroke; patients are at high risk of developing many adverse cardiac outcomes.[3] Cardiac Troponin T (cTnT) is highly sensitive and specific marker of cardiac damage.[4] Several studies have noticed that elevated levels of cTnT are increased in 10-34% of patients with acute ischemic stroke.[5] Although the exact cause of troponin rise in acute ischemic stroke is not clear, it is suggested that the reason for this cardiac change resulted from excessive sympathetic nervous activity secondary to insular cortical damage.[6] Some studies have reported an association between an elevated troponin level with both mortality and poor outcomes in acute ischemic stroke.[7] Again, the clinical significance of such association is not clear. To date, and up to our knowledge, there is no previous study done regarding the same subject in Erbil city. The objectives of this study are to (1) assess the correlation between elevated serum cTnT levels and stroke severity, and (2) determine the effect of elevated serum cTnT on in-hospital outcomes in a group of patients with acute ischemic stroke in Erbil city-Iraq.

Materials and Methods:

This observational, cross-sectional study was conducted in Rizgary teaching hospital, department of neurology between January 2016 and January 2017 .A total of 100 patients with a diagnosis of acute ischemic stroke were enrolled in this study. According to serum cTnT level, the patients were classified into two groups; group I (patients with normal cTnT level, n=61), and group II (patients with elevated cTnT level, n= 39).

The inclusion criteria were patients with (1) acute ischemic stroke confirmed by either computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain within 24-hours of stroke onset; and (2) measurement of serum cTnT level (normal value 0.0-0.3 ng/ml)[8] within 24-hours of stroke onset, to patients with age $\geq$ 18 years and of both genders.

The exclusion criteria were patients with recent ischemic heart disease (acute coronary syndrome according to American college of cardiology/ American Heart Association [ACC/AHA]) within 2 weeks prior to stroke onset, recent coronary angioplasty or coronary bypass surgery, and other heart diseases or conditions that might increase serum cTnT level, such as congestive heart failure, valvular heart disease, end-stage renal disease, acute pulmonary embolism, chest trauma, rabdomyolysis, and chemotherapy. Patients with intracerebral or subarachnoid hemorrhage were ruled out by brain CT scan at the time of admission. All patients were assessed by a detailed history, physical examination, CT scan or MRI of the brain, electrocardiography (ECG), echocardiographic evaluation and other investigational tools. Blood samples were drawn to measure the serum cTnT level and other hematological parameters for each patient. The cut-off value for elevated serum cTnT was more than 0.3 ng/ml. The severity of the stroke was evaluated according to the National institute of Health Stroke Scale (NIHSS) [9]. A score of 1-4 is considered minor stroke, 5-15 is moderate stroke, 16-20 is moderately severe and more than 21 is severe stroke. In-hospital outcomes such as aspiration pneumonia, seizures, hemorrhage inside infarction and death were evaluated in both groups.

The data were collected by interviewing the patients using a questionnaire designed by the researchers. The questionnaire included information about socio-demographic data (age, gender,..), and risk factors like hypertension and diabetes mellitus,

Ethical considerations: The study protocol was approved by the ethics committee of the College of Medicine, Hawler Medical University. This study was conducted by using an informed verbal consent from the patients prior to participation in the study. The purpose of the study was carefully explained to each patient.

Statistical analysis of data:

Data were analyzed using the statistical package for social sciences (SPSS, version 19). Student's t test for two independent samples was used to compare means. Correlation coefficient (r) was obtained to demonstrate the correlations between variables. A 'P' value of ≤ 0.05 was considered as statistically significant.

Results:

A total of 100 patients with acute ischemic stroke were enrolled in this study. Serum cTnT was elevated in 39 patients (39%). The patients were classified into two groups according to serum cTnT levels; group I (patients with normal cTnT level (0.0-0.3 ng/ml), n=61), and group II (patients with elevated cTnT level (more than 0.3 ng/ml), n= 39). Basic and clinical characteristics were compared between the two groups, as shown in Table 1. Patients with elevated cTnT levels were mainly males, had a higher prevalence of hypertension and diabetes mellitus than the normal cTnT group , and the differences were significant (P<0.001, for all). Systolic blood pressure (SBP) and total cholesterol were significantly higher (P<0.008 and <0.001, respectively) in group II patients than in group I. In addition, group II patients had more ECG changes, higher stroke scale and higher length of stay in hospital than in group I patients, and the differences were significant (P<0.001, for all).

Table 1: Basic and clinical characteristics of patients with normal and elevated serum cTnT levels.

Variables	Group I **Normal cTnT N=61**		Group II **Elevated cTnT** N=39		p
	Mean	**SD**	**Mean**	**SD**	
Age(y.)	66.1	11.66	65	10.8	0.6
Male (%)	47.5		58.9		<0.001
Hypertension (%)	65.5		74.3		<0.001
Diabetes (%)	32.7		53.8		<0.001
Systolic BP(mmHg)	152.2	24.8	165.5	22.8	0.008
Diastolic BP(mmHg)	87	13.1	91.9	12.8	0.07

Cholesterol(mg/dl)	178.5	52.1	187.6	31.4	0.001
TG(mg/dl)	122.9	67.42	136.9	78.2	0.36
LDL(mg/dl)	102.4	29.1	106.4	32.1	0.4
HDL(mg/dl)	39.6	12.4	35.5	9.3	0.06
BU(mg/dl)	42.7	15.9	44.5	22.1	0.6
SC(mg/dl)	1	0.31	1	0.44	0.48
ECG changes	3.2		33.3		<0.001
cTnT	0.1	0.03	49.9	144.8	<0.001
Stroke scale	4	3.5	9.7	5.3	<0.001
Length of stay(days)	5	2.3	7.4	3.7	<0.001

Table 2: Incidence of in-hospital outcomes in both studied groups.

Variables	Group I **Normal cTnT N=61**		Group II **Elevated cTnT** N=39		p
	N	**%**	**N**	**%**	
Aspiration pneumonia	5	8.1	5	12.8	<0.001
Seizures	0	0	2	5.1	<0.001
Hemorrhage	0	0	2	5.1	<0.001
Death	3	4.9	6	15.3	<0.001

Table 2 shows the incidence of in-hospital outcomes in both studied groups. The incidence of aspiration pneumonia, seizures, hemorrhage inside the infarcted area, and death was significantly higher (P<0.001, for all) in group II patients than in group I patients.

Discussion:

In the current study, high serum cTnT level was detected in 39% of patients with acute ischemic stroke, and was associated with severity and poor in-hospital outcomes. The prevalence of elevated cTnT level in acute ischemic stroke varies from study to study but has been reported to be as high as 34%.[5] In consistence with the present study, other studies have confirmed the presence of high troponin levels in ischemic stroke [5,10-12]. The relationship between cerebrovascular and cardiovascular disease is a little bit complex and the cause of troponin increment is still poorly understood. It has been suggested that the myocardial damage observed in acute stroke insult is due to myocyte damage (myocytolysis) due to activation of sympathoadrenal system that may be linked

to insular damage.[11] Epinephrine and cortisol concentrations are elevated after a stroke and higher levels have been reported in association with myocardial damage.[5] The brain-heart connection was described previously by Levy. He mentioned that changes in central nervous system metabolism can affect cardiac function.[14] Acute ischemic strokes can induce diffuse myocardial damage characterized by micro-islands of necrosis and subendocardial hemorrhage. [14]

In concordance with the present study, increased mortality has been predicted by elevated troponin levels in multiple studies [7.15,16]. Stroke can induce a considerable stress on the patient's heart causing troponin to be elevated and this might be an indication of a lower cardiac tolerance caused by the acute stroke.[17] This might explain the correlation of elevated serum cTnT with both the severity and the poor in-hospital outcomes found in this study and for this reason, doctors in charge of stroke unit should be more careful when dealing with these patients.

There is controversy whether troponin should be routinely checked in patients with acute stroke. Recent UK acute stroke guidelines from the National Institute of Clinical Excellence [18] and the Scottish Intercollegiate Guidelines Network [19] do not recommend the routine checking of cardiac enzymes. However, the American Stroke Association[20] does recommend this.

Conclusion:

Elevated serum cTnT levels in the absence of clinical evidence of recent coronary artery disease were associated with stroke severity, longer in-hospital stay and poor in-hospital outcome**s.**

Recommendations:

(1) A large prospective study with assessment of both short and long-term clinical outcomes is needed in future studies to clarify the clinical implications of high serum cTnT levels in acute ischemic stroke.

(2) We suggest that doctors in neurology unit would better consider adding a serum cTnT level to their routine testing when admitting patients with acute ischemic stroke.

Limitations:

Our study has few limitations. First, our sample study was low. A larger study population is needed in future. Second, we depend on single baseline blood sample in detecting cTnT level. Repeated assays could provide additional information on the evolution of myocardial damage.

Conflicts of interest:

The authors report no conflicts of interest

References:

1. Flegal RW, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.

2. James P., Ellis C. J., Whitlock R. M. L., McNeil A. R., Henley J., and Anderson N. E., "Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study," British Medical Journal 2000;vol. 320,no.7248,pp.1502–1504,.

3. Brickner ME. Cardioembolic stroke.AmJMed1996;100:465-74.

4. Babuin L. and Jaffe A. S., "Troponin: the biomarker of choice for the detection of cardiac injury," CMAJ 2005;vol. 173, no. 10, pp. 1191–1202,

5. Christensen H, Johannesen HH, Christensen AF, Bendtzen K, Boysen G: Serum cardiac Troponin I in acute stroke is related to serum cortisol and TNF-α. Cerebrovasc Dis 2004;18: 184-199.

6. Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ: Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. Cerebrovasc Dis 2007; 23: 2 60–266.

7. Di Angelantonio E, Fiorelli M, Toni D, Sacchetti ML, Lorenzano S, Falcou A, et al: Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 76–81.

8. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999 Jul. 45(7):1104-21.

9.Brott T, Adams HP Jr, Olinger CP .Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 ;20(7):864-70

10.Touz´e E.,Varenne O., Chatellier G., Peyrard S., Rothwell P.M., Mas J.L. "Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke :a systematic review and meta-analysis, "Stroke, 2005.vol.36,no.12,pp.2748–2755,

11. Ay H., Koroshetz W. J., Benner T. "Neuroanatomic correlates of stroke-related myocardial injury," Neurology 2006.vol. 66,no.9,pp.1325–1329,

12. Jensen J. K., Kristensen S. R., Bak S., Atar D., HøilundCarlsen P. F., and Mickley H., "Frequency and significance of troponin T elevation in acute ischemic stroke," The American Journal of Cardiology 2007,vol.99,no.1,pp.108–112,.

13. Levy A. The exiting causes of ventricular fibrillation in animals under chloroform anesthesia. Heart 1913; 4:319-78.

14.Jacob WA, Van Bogaert A, De Groodt-Lasseel MH. Myocardial ultrastructure and haemodynamic reactions during experimental subarachnoid haemorrhage. J Mol Cell Cardiol 1972;4:287-298.

15. Kerr G, Ray G, Wu O, Stott DJ, Langhorne P: Elevated troponin after stroke: a systematic review. Cerebrovasc Dis 2009, 28:220-226.

16. J.K.Jensen,D.Atar,andH.Mickley,"Mechanism of troponin elevations in patients with acute ischemic stroke," American JournalofCardiology,vol.99,no.6,pp.867–870,2007.

17. Scheitz J. F., Mochmann H.-C., Nolte C. H. "Troponin elevation in acute ischemic stroke (TRELAS): protocol of a prospective observational trial, "BMC Neurology 2011;vol.11,article no.1471.

18. National Institute of Clinical Excellence: Acute Stroke and TIA Clinical Guidelines (draft). London, NICE, 2008. http://www. nice.org.uk/guidance/index.jsp? action=byID&o=11646 (accessed June 26, 2008).

19.Scottish Intercollegiate Guidelines Network: Management of Patients with Stroke: Assessment, Investigation, Immediate Management and Secondary Prevention (draft). Glasgow, SIGN, 2008.

20.American Heart Association/American Stroke Association Guideline: Guidelines for the Early Management of Adults with Ischaemic Stroke. Dallas, AHA, 2007. http:// stroke.ahajournals.org/cgi/reprint/ STROKEAHA.107.181486 (accessed June 26, 2008).